<DOC>
	<DOCNO>NCT01185223</DOCNO>
	<brief_summary>The objective study assess efficacy safety oral valganciclovir versus intravenous ganciclovir patient follow allogenic stem cell transplantation .</brief_summary>
	<brief_title>Study Comparing Valganciclovir Versus Ganciclovir Patients Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Patient follow allogeneic SCT Patient first episode positive CMVPCR ( DNAemia ) pp65 antigenemia assay ( antigenemia ) 100 day SCT Absolute neutrophil count ( ANC ) ≥1000 cells/µL 2 consecutive followup within 10 day randomization Patient creatinine clearance ≥25 mL/min ( calculate CockcroftGault formula , see Part I Section 6.1.2 ) evidence improve renal function , None gastrointestinal graftversushost disease ( GVHD ) grade 2 Patient suspect diagnosed CMV disease Patient receive syngeneic SCT Patient receive investigational medicinal product ( IMP ) within last 30 day prior screen simultaneously participate another clinical study IMP Patient body weight &lt; 50 kg &gt; 95 kg , Patient receive antiCMV therapy within past 30 day prior screen ( use acyclovir , valacyclovir , famciclovir permit ) Patient participate study , Patient show neutropenia , thrombocytopenia , anemia within 10 day time point randomization follow : The ANC &lt; 1000 cells/μL 2 consecutive followup , A platelet count ≥25000/μL achieved/maintained platelet transfusion A hemoglobin level ≥8g/dL achieved/maintained red blood cell transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Valganciclovir</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Antiviral Drug</keyword>
	<keyword>CMV disease</keyword>
</DOC>